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Pain is an unpleasant sensation and it is widely accepted to be
one of the most important determinants of quality of life. A
study reported by the World Health Organization (WHO)
demonstrated that individuals who live with persistent pain
suffer fourfold more from depression (or) anxiety comparedto healthy subjects (Gureje et al., 1998). The identiﬁcation of
compounds able to treat both acute and chronic pain with lim-
ited side effects is one of the prominent goals in biomedical
research. Non-steroidal anti-inﬂammatory drugs (NSAIDs)
exert their effects by inhibition of prostaglandin production.
The pharmacological target of NSAIDs is cyclooxygenase
(COX), which catalyzes the ﬁrst committed step in arachidonic
acid metabolism. Two isoforms of the membrane protein COX
are known: COX-1, which is constitutively expressed in most
tissues, is responsible for the physiological production of pros-
taglandins; and COX-2, which is induced by cytokines, mito-
gens and endotoxins in inﬂammatory cells, is responsible for
the elevated production of prostaglandins during inﬂammation
(Kurumbail et al., 1996). The widely prescribed anti-inﬂamma-
tory pyrazole derivatives such as, Celecoxib, Deracoxib,
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Figure 1 Structures of well established NSAIDs and title
compounds with its common pharmacophore features.
Scheme 1 Pyrazole-4-carbaldehyde derivatives.
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Fig. 1 are COX inhibitors with reduced ulcerogenic side
effects. Due to the importance of pyrazole derivatives consid-
erable efforts have been made by several investigators, to pre-
pare new compounds bearing a single substituent or more
complicated systems, including the heterocyclic rings mainly
at 1-, 3- and 4-positions. Also, the literature survey reveals
excellent anti-inﬂammatory, analgesic (Farghaly et al., 2001;
Balsamo et al., 2003; Youssef et al., 2007; Souza et al., 2001;
Godoy et al., 2004; Souza et al., 2002; Prokopp et al., 2006),
anti-microbial (Pimerova et al., 2001; Bekhit et al., 2008),
anti-viral, anti-tumor (Park et al., 2005), anti-convulsant
(Michon et al., 1995), anti-histaminic (Yildirim et al., 2005)
and anti-depressant (Bailey et al., 1985) activities with some
compounds containing the heterocyclic ring such as pyrazole.
Based on the above mentioned research results, the objective
of this study aimed to synthesize some novel derivatives of 1-
(4-substitutedphenyl)-3-phenyl-1H-pyrazole-4-carbaldehyde
4a–l in order to screen them for anti-inﬂammatory and analge-
sic activities.
2. Experimental
2.1. Materials
Synthetic starting material, reagents and solvents were of ana-
lytical grade or of the highest quality commercially available.The chemicals were purchased from Aldrich Chemical Co.,
and Merck Chemical Co., respectively, these solvents used
were of analytical grade and puriﬁed before their use.
2.2. Instrumentation
The silica gel G used for analytical chromatography (TLC) was
obtained from E. Merck India Ltd. Solvent systems used were
CHCl3–MeOH (7:3). All the melting points were taken in an
open glass capillary and are uncorrected. 1HNMR spectra were
taken on a Bruker ultra shield (300 MHz)NMR spectrometer in
CDCl3 using tetramethylsilane [(CH3)4Si] as an internal stan-
dard. Chemical shifts (d) are expressed in ppm. Mass spectra
were obtained on a JEOL-SX-102 instrument using electron
impact ionization. All the IR spectra were recorded in KBr pel-
lets on a JascoFT-IR410 spectrometer. Elemental analyseswere
performed on a Perkin Elmer model 240c analyzer and were
within ±0.4% of the theoretical values.
2.3. General procedure
The synthetic strategy of the target compounds is illustrated in
Scheme 1. The acetophenone (0.01 mol), substituted phenyl
hydrazine (0.01 mol) and DMF (0.5 mL) were exposed to
microwave at 200 W intermittently at 10 s intervals. The spec-
iﬁed reaction time of 3 min was observed of compound 1-
substituted phenyl-2-(1-phenylethylidene)hydrazine 3. The
reaction mixture was cooled with cold water. The precipitate
thus obtained was ﬁltered, washed with water and puriﬁed
by recrystallization from ethanol to furnish 3. The compound
3 (0.01 mol) was added portion wise with Vilsmeier-Haack
reagent (POCl3–DMF/SiO2) (0.03 mol). After the addition
was complete, the reaction ﬂask was kept at room temperature
for 5 min and silica gel 3 g was added and properly mixed with
the help of a glass rod, till free ﬂowing powder was obtained.
The powder is then irradiated in a microwave oven at 400 W
intermittently at 30 s intervals. The speciﬁed reaction time of
5 min was observed of compound 4a–l. The reaction mixture
was cooled and treated with cold water. The solid obtained
by the neutralization of the ﬁltrate with NaHCO3 was ﬁltered,
washed with water and puriﬁed by recrystallization from meth-
anol to afford 4a–l. The completion of reaction is monitored
by TLC method [eluent: CHCl3–MeOH (7:3)].
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Yield: 79%; mp. 173–175 C, IR (KBr) cm1: 3342 (N–H
stretching), 3012 (Ar-CH), 1541 (C‚N), 1481 (C‚C), 1331
(N–H bending); 1H NMR (300 MHz, CDCl3, d ppm): 7.98
(s, 1H, N–H), 6.12–7.22 (m, 10H, Ar-H), 2.27 (m, 3H, –
CH3); MS (EI) m/z: [M]
+ 210; (Calcd for C14H14N2; 210.27).
Anal. Calcd for C14H14N2; C, 79.97; H, 6.71; N, 13.32; Found:
C, 80.03; H, 6.72; N, 13.34.
2.3.2. 1,3-Diphenyl-1H-pyrazole-4-carbaldehyde (4a)
Yield: 82%; mp. 189–191 C, IR (KBr) cm1: 3036 (Ar-CH),
2756 (C–H in CHO), 1706 (C‚O), 1552 (C‚N), 1481
(C‚C); 1H NMR (300 MHz, CDCl3, d ppm): 8.79 (s, 1H, –
CHO), 7.49 (s, 1H, Pyrazole-CH), 6.29–7.19 (m, 10H, Ar-H);
MS (EI) m/z: [M]+ 248; (Calcd for C16H12N2O; 248.28). Anal.
Calcd for C16H12N2O; C, 77.40; H, 4.87; N, 11.28; Found: C,
77.62; H, 4.88; N, 11.26.
2.3.3. 1-(2-Methylphenyl)-3-diphenyl-1H-pyrazole-4-
carbaldehyde (4b)
Yield 76%, mp. 172–174 C; IR (KBr) cm1: 3031 (Ar-CH),
2774 (C–H in CHO), 1713 (C‚O), 1543 (C‚N), 1484
(C‚C); 1H NMR (300 MHz, CDCl3, d ppm): 8.34 (s, 1H, –
CHO), 7.44 (s, 1H, Pyrazole-CH), 6.33–7.14 (m, 9H, Ar-H),
2.71 (m, 3H, –CH3); MS (EI) m/z: [M]
+ 262; (Calcd for
C17H14N2O; 262.31). Anal. Calcd for C17H14N2O; C, 77.84;
H, 5.38; N, 10.68; Found: C, 77.56; H, 5.40; N, 10.69.
2.3.4. 1-(4-Methylphenyl)-3-diphenyl-1H-pyrazole-4-
carbaldehyde (4c)
Yield 72%, mp. 167–169 C; IR (KBr) cm1: 3012 (Ar-CH),
2748 (C–H in CHO), 1719 (C‚O), 1512 (C‚N), 1474
(C‚C); 1H NMR (300 MHz, CDCl3, d ppm): 8.19 (s, 1H, –
CHO), 7.46 (s, 1H, Pyrazole-CH), 6.61–7.21 (m, 9H, Ar-H),
2.19 (m, 3H, -CH3); MS (EI) m/z: [M]
+ 262; (Calcd for
C17H14N2O; 262.31). Anal. Calcd for C17H14N2O; C, 77.84;
H, 5.38; N, 10.68; Found: C, 77.62; H, 5.39; N, 10.71.
2.3.5. 1-(2-Hydroxyphenyl)-3-diphenyl-1H-pyrazole-4-
carbaldehyde (4d)
Yield 81%, mp. 171–173 C; IR (KBr) cm1: 3413 (Ar-OH),
3016 (Ar-CH), 2762 (C–H in CHO), 1718 (C‚O), 1572
(C‚N), 1472 (C‚C); 1H NMR (300 MHz, CDCl3, d ppm):
9.91 (s, 1H; Ar-OH), 8.74 (s, 1H, –CHO), 7.79 (s, 1H, Pyra-
zole-CH), 6.51–7.22 (m, 9H, Ar-H); MS (EI) m/z: [M]+ 264;
(Calcd for C16H12N2O2; 264.28). Anal. Calcd for
C16H12N2O2; C, 72.72; H, 4.58; N, 10.60; Found: C, 72.92;
H, 4.60; N, 10.62.
2.3.6. 1-(4-Hydroxyphenyl)-3-diphenyl-1H-pyrazole-4-
carbaldehyde (4e)
Yield 84%, mp. 161–163 C; IR (KBr) cm1: 3402 (Ar-OH),
3031 (Ar-CH), 2788 (C–H in CHO), 1712 (C‚O), 1522
(C‚N), 1483 (C‚C), 1H NMR (300 MHz, CDCl3, d ppm):
9.93 (s, 1H; Ar-OH), 8.42 (s, 1H, –CHO), 7.31 (s, 1H, Pyra-
zole-CH), 6.16–6.98 (m, 9H, Ar-H); MS (EI) m/z: [M]+ 264;
(Calcd for C16H12N2O2; 264.28). Anal. Calcd for
C16H12N2O2; C, 72.72; H, 4.58; N, 10.60; Found: C, 72.81;
H, 4.60; N, 10.61.2.3.7. 1-(2-Flurophenyl)-3-phenyl-1H-pyrazole-4-carbaldehyde
(4f)
Yield: 73%; mp. 182–184 C, IR (KBr) cm1: 3044 (Ar-CH),
2770 (C–H in CHO), 1712 (C‚O), 1532 (C‚N), 1471
(C‚C), 1029 (C–F); 1H NMR (300 MHz, CDCl3, d ppm):
8.71 (s, 1H, –CHO), 7.59 (s, 1H, Pyrazole-CH), 6.54–7.17
(m, 9H, Ar-H), MS (EI) m/z: [M]+ 266; (Calcd for C16H11FN2-
O; 266.27). Anal. Calcd for C16H11FN2O; C, 72.17; H, 4.16; N,
10.52; Found: C, 72.26; H, 4.18; N, 10.56.
2.3.8. 1-(4-Flurophenyl)-3-phenyl-1H-pyrazole-4-carbaldehyde
(4g)
Yield: 76%; mp. 174–176 C, IR (KBr) cm1: 3061 (Ar-CH),
2758 (C–H in CHO), 1697 (C‚O), 1511 (C‚N), 1501
(C‚C), 1032 (C–F); 1H NMR (300 MHz, CDCl3, d ppm):
8.31 (s, 1H, –CHO), 7.49 (s, 1H, Pyrazole-CH), 6.24–7.01
(m, 9H, Ar-H); MS (EI) m/z: [M]+ 266; (Calcd for C16H11FN2-
O; 266.27). Anal. Calcd for C16H11FN2O; C, 72.17; H, 4.16; N,
10.52; Found: C, 72.42; H, 4.18; N, 10.55.
2.3.9. 1-(2-Bromophenyl)-3-phenyl-1H-pyrazole-4-
carbaldehyde (4h)
Yield: 78%; mp. 177–179 C, IR (KBr) cm1: 3039 (Ar-CH),
2766 (C–H in CHO), 1712 (C‚O), 1561 (C‚N), 1489
(C‚C), 606 (C–Br); 1H NMR (300 MHz, CDCl3, d ppm):
8.12 (s, 1H, –CHO), 7.62 (s, 1H, Pyrazole-CH), 7.12–7.49
(m, 9H, Ar-H); MS (EI) m/z: [M + 2] 329; (Calcd for C16H11-
BrN2O; 327.18). Anal. Calcd for C16H11BrN2O; C, 58.74; H,
3.39; N, 8.56; Found: C, 58.91; H, 3.40; N, 8.54.
2.3.10. 1-(4-Bromophenyl)-3-phenyl-1H-pyrazole-4-
carbaldehyde (4i)
Yield: 72%; mp. 172–174 C, IR (KBr) cm1: 3018 (Ar-CH),
2781 (C–H in CHO), 1722 (C‚O), 1543 (C‚N), 1493
(C‚C), 662 (C–Br); 1H NMR (300 MHz, CDCl3, d ppm):
8.23 (s, 1H, –CHO), 7.81 (s, 1H, Pyrazole-CH), 6.32–7.49
(m, 9H, Ar-H); MS (EI) m/z: [M + 2] 329; (Calcd for C16H11-
BrN2O; 327.18). Anal. Calcd for C16H11BrN2O; C, 58.74; H,
3.39; N, 8.56; Found: C, 58.82; H, 3.40; N, 8.57.
2.3.11. 1-(2-Chlorophenyl)-3-phenyl-1H-pyrazole-4-
carbaldehyde (4j)
Yield: 83%; mp. 163–165 C, IR (KBr) cm1: 3052 (Ar-CH),
2743 (C–H in CHO), 1716 (C‚O), 1564 (C‚N), 1492
(C‚C), 794 (C–Cl); 1H NMR (300 MHz, CDCl3, d ppm):
8.96 (s, 1H, –CHO), 7.97 (s, 1H, Pyrazole-CH), 6.52–7.72
(m, 9H, Ar-H); MS (EI) m/z: [M + 2] 284; (Calcd for C16H11-
ClN2O; 282.72). Anal. Calcd for C16H11ClN2O; C, 67.97; H,
3.92; N, 9.91; Found: C, 68.02; H, 3.93; N, 9.93.
2.3.12. 1-(4-Chlorophenyl)-3-phenyl-1H-pyrazole-4-
carbaldehyde (4k)
Yield: 84%; mp. 180–182 C, IR (KBr) cm1: 3061 (Ar-CH),
2778 (C–H in CHO), 1712 (C‚O), 1523 (C‚N), 1477
(C‚C), 791 (C–Cl); 1H NMR (300 MHz, CDCl3, d ppm):
8.91 (s, 1H, –CHO), 7.89 (s, 1H, Pyrazole-CH), 6.12–7.42
(m, 9H, Ar-H); MS (EI) m/z: [M + 2] 284; (Calcd for C16H11-
ClN2O; 282.72). Anal. Calcd for C16H11ClN2O; C, 67.97; H,
3.92; N, 9.91; Found: C, 68.21; H, 3.93; N, 9.92.
1018 T.P. Selvam et al.2.3.13. 1-(4-Acetamidophenyl)-3-phenyl-1H-pyrazole-4-
carbaldehyde (4l)
Yield: 82%; mp. 182–184 C, IR (KBr) cm1: 3329 (N–H
stretching), 3064 (Ar-CH), 2792 (C–H in CHO), 1717
(C‚O), 1552 (C‚N), 1471 (C‚C), 1326 (N–H bending);
1H NMR (300 MHz, CDCl3, d ppm): 8.82 (s, 1H, –CHO),
7.91 (s, 1H, N–H), 7.44 (s, 1H, Pyrazole-CH), 6.17–7.10 (m,
9H, Ar-H), 2.78 (s, 3H, –CH3); MS (EI) m/z: [M]
+ 305; (Calcd
for C18H15N3O2; 305.33). Anal. Calcd for C18H15N3O2; C,
70.81; H, 4.95; N, 13.76; Found: C, 70.94; H, 4.96; N, 13.78.
2.4. Pharmacology
The synthesized compounds were evaluated for anti-inﬂamma-
tory, analgesic and ulcerogenic activities. One-way analysis of
variance (ANOVA) was performed to ascertain the signiﬁ-
cance of all the exhibited activities. The test compounds and
the standard drugs were administered in the form of a suspen-
sion (1% carboxy methyl cellulose as a vehicle) by oral route of
administration for anti-inﬂammatory and analgesic but for
ulcerogenicity studies by intraperitoneally as suspension in
10% v/v Tween-80. Each group consisted of six animals. The
animals were maintained in colony cages at 25 ± 2 C, relative
humidity of 45–55%, under a 12 h light and dark cycle; were
fed standard animal feed (Olfert et al., 1993). All the animals
were acclimatized for a week before use.
2.4.1. Anti-inﬂammatory activity
Anti-inﬂammatory activity was evaluated by carrageenan-
induced paw edema test in rats (Winter et al., 1962). Diclofe-
nac sodium 10 and 20 mg/kg was administered as standard
drug for comparison. The test compounds were administered
at two dose levels (10 and 20 mg/kg). The paw volumes were
measured using the mercury displacement technique with the
help of plethysmograph immediately before and 30 min, 1, 2
and 3 h after carrageenan injection. The percent inhibition of
paw edema was calculated according to the following formula:
%Inhibition I ¼ 100½1 ða xÞ=ðb yÞ;
where x is the mean paw volume of rats before the administra-
tion of carrageenan and test compounds or reference com-
pounds (test group), a is the mean paw volume of rats after
the administration of carrageenan in the test group (drug trea-
ted), b is the mean paw volume of rats after the administration
of carrageenan in the control group, y is the mean paw volume
of rats before the administration of carrageenan in the control
group.
2.4.2. Analgesic activity
The analgesic activity was performed by tail-ﬂick technique
using Wistar albino mice (25–35 g) of either sex selected by
random sampling technique (Kulkarni, 1980; Amour and
Smith, 1941). Diclofenac sodium at a dose level of 10 and
20 mg/kg was administered orally as the reference drug for
comparison. The test compounds at two dose levels (10 and
20 mg/kg) were administered orally. The reaction times were
recorded at 30 min, 1, 2 and 3 h after the treatment and the
cut-off time was 10 s. The percent analgesic activity (PAA)
was calculated by the following formula:
PAA ¼ ½T2  T1=10 T1  100;where T1 is the reaction time (s) before treatment and T2 is the
reaction time (s) after treatment.
2.4.3. Ulcerogenicity
Ulceration in rats was induced as reported by (Goyal et al.,
1985). Albino rats of Wistar strain weighing 150–200 g of
either sex were divided into various groups each of six animals.
Control group of animals were administered only with 10% v/
v Tween-80 suspension intraperitoneally. One group was
administered with Aspirin intraperitoneally at a dose of
200 mg/kg once daily for three days. Diclofenac was also
administered as the standard drug at 20 mg/kg once daily for
3 days to another group of animals in the same route. The
remaining group of animals were administered with test com-
pounds intraperitoneally at a dose of 20 mg/kg. On the fourth
day, pylorus was ligated as per the method of (Shay et al.,
1945). Animals were fasted for 36 h before the pylorus ligation
procedure. Four hours after the ligation, animals were sacri-
ﬁced. The stomach was removed and opened along the greater
curvature. Ulcer index was determined by the method of
Ganguly and Bhatnagar (1973).
3. Results and discussion
3.1. Chemistry
The series of heterocycles, 1-(4-substitutedphenyl)-3-phenyl-
1H-pyrazole-4-carbaldehyde 4a–l was synthesized by the reac-
tion of acetophenone with substituted phenyl hydrazine in the
presence of Vilsmeier-Haack reagent. The IR, 1H NMR, mass
spectroscopy and elemental analysis for the new compound is
in accordance with the assigned structures. The IR spectra of
the prepared 1-phenyl-2-(1-phenylethylidene)hydrazine 3 and
pyrazole-4-carbaldehyde 4a–l revealed the disappearance of
respective N–H stretching and bending absorption (3342 and
1331 cm1) and the appearance of the characteristic carbonyl
(C‚O) band ranging from 1697 to 1722 cm1. It is noteworthy
to focus on the change in the carbonyl group of pyrazole-4-carb-
aldehyde 4a–l. The 1HNMRspectra of the prepared 1-phenyl-2-
(1-phenylethylidene)hydrazine 3 showed N–H signal in the
range of d 7.98 (s) and pyrazole-4-carbaldehyde (–CHO) proton
of synthesized compounds appeared as a singlet in the range of d
8.12–8.96. The disappearance of the respective N–H signal and
appearance of the –CHO singlet conﬁrm the presence of a pyra-
zolemoiety.All these observed facts clearly demonstrate that the
intermediate 3 is converted into 1-(4-substitutedphenyl)-3-phe-
nyl-1H-pyrazole-4-carbaldehyde 4a–l.
3.2. Pharmacology
Twelve derivatives were synthesized and their structures were
conﬁrmed by IR, NMR, mass spectroscopy and elemental
analysis. All the 12 derivatives were tested for their anti-
inﬂammatory activity by carrageenan-induced paw edema test
and analgesic activity by tail-ﬂick test. The results of anti-
inﬂammatory and analgesic testing indicate that the test com-
pounds exhibited moderate activity at 30 min of reaction time
and an increase in activity at 1 h, which reached a peak level at
2 h. Decline in activity, was observed at 3 h. The results of the
anti-inﬂammatory and analgesic evaluation of the tested com-
pounds are presented in Table 1, Figs. 2 and 3.
Table 1 Anti-inﬂammatory, analgesic activities and ulcer index of the synthesized compounds (4a–l).
Compounds Dose (mg/kg) Percentage analgesic activitya Percentage protection in paw edemaa Ulcer indexa
30 min 1 h 2 h 3 h 30 min 1 h 2 h 3 h
4a 10 22 ± 1.36* 26 ± 1.54* 29 ± 1.02** 25 ± 1.43* 15 ± 1.56* 23 ± 1.07* 30 ± 1.51* 17 ± 1.50* 0.62 ± 0.45*
20 29 ± 1.41* 46 ± 1.90** 42 ± 1.24** 29 ± 1.47* 37 ± 1.51** 42 ± 1.91** 50 ± 1.57** 34 ± 1.27*
4b 10 15 ± 1.70NS 19 ± 1.27* 24 ± 1.90* 18 ± 1.44* 12 ± 1.23* 14 ± 1.93* 21 ± 1.37* 11 ± 1.90* 0.78 ± 0.34
20 30 ± 1.01** 37 ± 1.57** 45 ± 1.01** 20 ± 1.32* 30 ± 1.26* 34 ± 1.71** 38 ± 1.87* 26 ± 1.50*
4c 10 24 ± 1.37** 29 ± 1.70*** 33 ± 1.60*** 30 ± 1.07* 19 ± 1.67** 24 ± 1.69** 37 ± 1.34*** 20 ± 1.15* 0.51 ± 0.29*
20 42 ± 1.61*** 52 ± 1.43*** 56 ± 1.86*** 35 ± 1.43* 40 ± 1.87** 48 ± 1.47*** 55 ± 1.87*** 38 ± 1.60*
4d 10 12 ± 1.51* 17 ± 1.48* 20 ± 1.02* 15 ± 1.81* 09 ± 1.71* 11 ± 1.51* 18 ± 1.92* 11 ± 1.04* 0.73 ± 0.35*
20 29 ± 1.91* 35 ± 1.50* 33 ± 1.00** 18 ± 1.44* 28 ± 1.91* 30 ± 1.50** 35 ± 1.16** 25 ± 1.92*
4e 10 25 ± 1.72** 28 ± 1.72*** 31 ± 1.57*** 27 ± 1.45* 18 ± 1.43** 24 ± 1.58* 35 ± 1.91** 19 ± 1.16* 0.56 ± 0.36*
20 40 ± 1.36** 49 ± 1.53*** 52 ± 1.82*** 33 ± 1.36* 39 ± 1.26*** 45 ± 1.62*** 53 ± 1.51*** 38 ± 1.26*
4f 10 20 ± 1.12** 25 ± 1.27*** 18 ± 1.43*** 23 ± 1.36* 14 ± 1.24** 20 ± 1.15* 25 ± 1.42** 14 ± 1.29* 0.76 ± 0.65*
20 35 ± 1.50*** 41 ± 1.77* 40 ± 1.01*** 25 ± 1.46* 34 ± 1.91* 38 ± 1.27** 42 ± 1.90** 31 ± 1.23*
4g 10 29 ± 1.37** 36 ± 1.70*** 40 ± 1.60*** 35 ± 1.07* 24 ± 1.42** 30 ± 1.91*** 46 ± 1.01** 25 ± 1.41* 0.40 ± 0.43*
20 49 ± 1.61*** 59 ± 1.43*** 68 ± 1.83 *** 43 ± 1.43* 47 ± 1.82*** 56 ± 1.76*** 65 ± 1.47*** 44 ± 1.15*
4h 10 20 ± 1.72** 23 ± 1.72* 27 ± 1.57*** 21 ± 1.45* 13 ± 1.67** 17 ± 1.69** 28 ± 1.34*** 12 ± 1.15* 0.71 ± 0.21*
20 33 ± 1.36** 40 ± 1.53* 39 ± 1.82*** 24 ± 1.36* 33 ± 1.87** 35 ± 1.47*** 40 ± 1.87*** 31 ± 1.60*
4i 10 27 ± 1.70NS 33 ± 1.27* 38 ± 1.90* 34 ± 1.44* 23 ± 1.42** 27 ± 1.91*** 40 ± 1.01** 23 ± 1.41* 0.44 ± 0.26*
20 46 ± 1.01** 57 ± 1.57** 62 ± 1.01** 40 ± 1.32* 46 ± 1.57* 52 ± 1.01** 61 ± 1.54*** 43 ± 1.92*
4j 10 17 ± 1.37** 22 ± 1.70* 22 ± 1.60* 20 ± 1.07* 13 ± 1.47* 15 ± 1.05* 24 ± 1.33* 11 ± 1.91* 0.81 ± 0.35*
20 34 ± 1.61*** 38 ± 1.43* 36 ± 1.61NS 22 ± 1.43* 31 ± 1.91* 36 ± 1.27* 39 ± 1.90* 28 ± 1.23*
4k 10 26 ± 1.37** 31 ± 1.70*** 35 ± 1.60*** 32 ± 1.07* 21 ± 1.47* 26 ± 1.05* 39 ± 1.33* 22 ± 1.91* 0.47 ± 0.26*
20 45 ± 1.61*** 55 ± 1.43*** 59 ± 1.61NS 38 ± 1.43* 44 ± 1.91*** 51 ± 1.27*** 58 ± 1.90*** 41 ± 1.23*
4l 10 23 ± 1.37** 27 ± 1.70*** 32 ± 1.60*** 28 ± 1.07* 16 ± 1.47* 25 ± 1.05* 34 ± 1.33* 17 ± 1.91* 0.49 ± 0.23*
20 39 ± 1.61*** 47 ± 1.43*** 57 ± 1.61*** 30 ± 1.43* 38 ± 1.91*** 43 ± 1.27*** 50 ± 1.90*** 36 ± 1.23*
Control – 2 ± 0.33NS 6 ± 0.47NS 4 ± 0.57NS 4 ± 0.89NS 5 ± 0.27NS 6 ± 0.25 NS 5 ± 0.30 NS 3 ± 0.91 NS 0.18 ± 0.10*
Diclofenac 10 25 ± 1.67* 31 ± 1.40* 42 ± 0.90* 31 ± 0.96* 20 ± 0.61* 26 ± 1.56* 49 ± 1.95* 21 ± 0.91* 1.49 ± 0.78**
20 44 ± 0.93* 53 ± 1.14** 71 ± 1.47*** 37 ± 1.11* 43 ± 0.59** 50 ± 0.90*** 78 ± 1.50*** 40 ± 1.34**
Aspirin 20 – – – – – – – – 1.21 ± 0.59**
Each value represents the mean ± SEM (n= 6); NS: non-signiﬁcant.
a Data expressed as mean ± SD.
* Signiﬁcance levels p< 0.05 as compared with the respective control.
** Signiﬁcance levels p< 0.01 as compared with the respective control.
*** Signiﬁcance levels p< 0.001 as compared with the respective control.
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Figure 2 Anti-inﬂammatory activity of the synthesized com-
pounds (4a–l).
Figure 3 Analgesic activity of the synthesized compounds (4a–l).
1020 T.P. Selvam et al.3.2.1. Anti-inﬂammatory activity
Results revealed that all of the tested compounds showed a
variant signiﬁcant anti-inﬂammatory activity. It is obvious
that most of the tested pyrazole-4-carbaldehydes 4c, 4e, 4g,
4i, 4k and 4l revealed relatively higher activities. The results
also revealed that in some cases, the presence of the para posi-
tion halogen moieties 4g, 4i and 4k enhances the anti-inﬂam-
matory activity in comparison with their corresponding para
position derivatives such as in compounds 4c, 4e and 4l. It is
obvious that this is a direct correlation between enhancement
of the anti-inﬂammatory activity and the presence of para
position halogen moieties. Data in Table 1 revealed that the
compounds 4c, 4e, 4g, 4i, 4k and 4l showed higher anti-inﬂam-
matory activities ranging from 53% to 65% at a dose of
20 mg/kg and 35 to 46% at a dose of 10 mg/kg respectively.
The most potent compound was 4 g with anti-inﬂammatory
activity of 65% at a dose of 20 mg/kg and 46% at a dose of
10 mg/kg, whereas compounds with unsubstituted and ortho
derivatives such as 4a, 4b, 4d, 4f, 4h and 4j exhibited lower
anti-inﬂammatory activities ranging from 35% to 50% at a
dose of 20 mg/kg and from 18% to 30% at a dose of 10 mg/
kg, respectively.
3.2.2. Analgesic activity
The results showed that most of the tested compounds with
para substitutions have a signiﬁcant analgesic effect. Com-
pounds 4g, 4i and 4k containing –F, –Br and –Cl substitutions
at the para position showed signiﬁcant activity while, com-
pounds 4c, 4e and 4l containing –CH3, –OCH3, and –NHC-
OCH3 substitutions at the para position exhibited little lesser
signiﬁcant activity. Moreover, compound 4 g showed a highest
analgesic activity of 68% at a dose of 20 mg/kg and 40% at a
dose of 10 mg/kg. Results revealed that the compounds 4c, 4e,
4g, 4i, 4k and 4l showed higher activities ranging from 52% to
68% at a dose of 20 mg/kg and 31% to 40% at a dose of
10 mg/kg, respectively, whereas compounds with unsubstituted
and ortho derivatives such as 4a, 4b, 4d, 4f, 4h and 4j exhibited
lowest analgesic activities ranging from 33% to 45% at a dose
of 20 mg/kg and from 18% to 29% at a dose of 10 mg/kg,
respectively.
On correlating the structures of the synthesized compounds
with their anti-inﬂammatory activity, it has been observed
that, out of the various phenyl substituted derivatives (4a–l),
six compounds (4g> 4i> 4k> 4l> 4c> 4e) exhibited sig-
niﬁcant anti-inﬂammatory and analgesic activities. All the
above mentioned six compounds were p-substituted.
3.2.3. Ulcer index
The ulcer index of the test compounds revealed that the com-
pounds with para substituents (4g, 4i, 4k, 4l, 4c and 4e) showed
a negligible ulcer index, whereas those with unsubstituted com-
pound (4a) (ulcer index 0.62 ± 0.45) exhibited little increase in
ulcer index and the ortho substituted derivatives (4b, 4d, 4f, 4h
and 4j) exhibited higher ulcer index over other test compounds.
When compared with the reference standard Diclofenac
sodium (1.49 ± 0.78) and Aspirin (1.21 ± 0.59) ulcer index
the test compounds exhibited only 0.40 ± 0.43% to
0.81 ± 0.35% of the ulcer index. Among the title compounds,
1-(2-hydroxyphenyl)-3-diphenyl-1H-pyrazole-4-carbaldehyde
(4j) showed the highest (ulcer index 0.81 ± 0.65). The results
of the tested compounds are given in Table 1.3.3. Structure–activity relationship studies
Structure–activity relationship studies revealed that different
substitutions on the pyrazole nucleus exerted remarkable bio-
logical activity. The electronic nature of the substituent groups
at para positions in the phenyl ring played a signiﬁcant role in
anti-inﬂammatory and analgesic activities. The observed data
showed that the para substituted derivatives exhibited better
activity than other ortho and unsubstituted derivatives.
Among the different substitutions at para position halogen
analogs showed better activity in order (4g> 4i> 4k), respec-
tively, than methyl, hydroxy and nitro substituted compounds.
The studies revealed that the position of the substituted group
on the phenyl ring appeared to greatly inﬂuence the pharmaco-
logical activity.
4. Conclusion
In summary, a new series of pyrazole derivatives have been
prepared and fully assigned by analytical and spectral data.
The results of the analgesic and anti-inﬂammatory activities
of the synthesized compounds showed moderate enhancement
of the activity. The compounds 4g, 4i and 4k exhibited good
anti-inﬂammatory and analgesic activities. Interestingly this
compound showed one-third of the ulcer index of the reference
i.e. Diclofenac and Aspirin. Among all the synthesized com-
pounds, p-substituted derivatives showed excellent activities.
Hence this analog could be developed as a new class of anti-
inﬂammatory and analgesic agents. However, further struc-
Microwave-assisted synthesis, characterization and biological activity 1021tural modiﬁcation is planned to enhance the anti-inﬂammatory
and analgesic activities with the decreased ulcerogenic index.
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